Results 21 to 30 of about 2,820 (114)

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis [PDF]

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF.
Ailsa Hart, Seyedehsan Navabi, Geert D'Haens, Katsuyoshi Matsuoka, María Dolores Martín‐Arranz, Raja Atreya, Karen Hamrick Samaan, Endip Dhesi, Isabel Redondo, Baojin Zhu, Jerome Paulissen, Liliana Zaremba‐Pechmann, Simin Baygani, Jimmy Limdi, David Laharie, Silvio Danese   +15 more
wiley   +2 more sources

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab [PDF]

ClinicoEconomics and Outcomes Research, 2019
Lorie A Ellis,1 Elisabetta Malangone-Monaco,2 Helen Varker,3 Diana Stetsovsky,3 Maureen Kubacki,1 Raphael J DeHoratius,1,4 Shelly Kafka1 1Real World Value and Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA; 2Life Sciences, IBM Watson Health,
Ellis LA, Malangone-Monaco E, Varker H, Stetsovsky D, Kubacki M, DeHoratius RJ, Kafka S   +6 more
doaj   +2 more sources

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis [PDF]

JCR: Journal of Clinical Rheumatology, 2022
Deodhar, Atul, Chakravarty, Soumya D., Shiff, Natalie J., Lo, Kim Hung, Xu, Stephen, Hsia, Elizabeth C., Danve, Abhijeet, Reveille, John D.   +7 more
openaire   +3 more sources

A Systematic Review of Literature: TNF‐α Blockers and JAK Inhibitors for the Treatment of Stevens‐Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme [PDF]

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Stevens‐Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme major (EM major) are severe dermatologic conditions characterized by varying degrees of skin detachment and involvement of mucosal membranes, often triggered by drug reactions or infections.
Sadaf Salehi, Pooneh Torabi, Mahsa Abbaspour, Nima Hajizadeh, Sara Sadeghi, Alireza Jafarzadeh, Azadeh Goodarzi   +6 more
wiley   +2 more sources

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative [PDF]

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +2 more sources

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain [PDF]

Farmacia Hospitalaria, 2014
Objective: To compare the cost of treating rheumatoid arthritis patients that have failed an initial treatment with methotrexate, with subcutaneous aba - tacept versus other first-line biologic disease-modifying antirheumatic drugs. Method: Subcutaneous
R. Ariza, A. van Walsem, C. Canal, C. Roldán, L. Betegón, I. Oyagüez, K. Janssen   +6 more
doaj   +1 more source

GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS

Вопросы современной педиатрии, 2012
The article represents the results of efficacy and safety evaluation of the human monoclonal antibodies — golimumab, according to the data of international multicenter randomized double-blind placebo-controlled trials, including patients with active ...
R. V. Denisova, E. I. Alexeeva
doaj   +1 more source

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis

Качественная клиническая практика, 2020
Rationale. Rheumatoid arthritis (RA) and systemic juvenile arthritis (sJA) are the most frequent rheumatic diseases in adults and adolescents, consequently. Biologics disease modifying antirheumatic drugs (bDMARDs) are eff ective in treatment of RA and s
A. S. Kolbin, A. A. Kurylev, S. A. Mishinova, Yu. E. Balykina, M. A. Proskurin   +4 more
doaj   +1 more source

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study

ACR Open Rheumatology, 2020
Objective To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis.
Philip Mease, M. Elaine Husni, Soumya D. Chakravarty, Shelly Kafka, Dennis Parenti, Lilianne Kim, Kim Hung Lo, Elizabeth C. Hsia, Arthur Kavanaugh   +8 more
doaj   +1 more source

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

BMC Rheumatology, 2020
Background Long-term clinical registries are essential tools to evaluate new therapies in a patient population that differs from those in randomized clinical trials. The objectives are to describe the profile of rheumatoid arthritis (RA) patients treated
Proton Rahman, Philip Baer, Ed Keystone, Denis Choquette, Carter Thorne, Boulos Haraoui, Andrew Chow, Rafat Faraawi, Wojciech Olszynski, John Kelsall, Emmanouil Rampakakis, Allen J. Lehman, Francois Nantel   +12 more
doaj   +1 more source